Nephrocare India raises Rs 8.08 crore in pre-IPO round

The fresh infusion of capital will fuel Nephrocare India's target of establishing 22 high-end kidney care facilities across India by March 2026.

Published On 2024-01-01 07:40 GMT   |   Update On 2024-03-27 07:51 GMT
Advertisement

Kolkata: Nephrocare India, a Kolkata-based comprehensive renal care institution, has raised Rs 8.08 crore in its pre-IPO round paving the way for its expansion plans, the company said on Friday.

The funding saw participation from marquee investors, who include former HDFC chairman Deepak Parekh, HDFC Securities chairman Bharat Shah, and founder and MD of Macleods Pharmaceuticals Rajendra Agarwal, it said.

Advertisement
The fresh infusion of capital will fuel Nephrocare India's target of establishing 22 high-end kidney care facilities across India by March 2026. Four centres are expected to be operational by the end of the current fiscal, the company said in a statement.
Its long-term vision is to establish 300 Nephrocare centres across the country within the next 8-10 years.
Highlighting the critical need for such expansion, company officials pointed out the vast demand for kidney care units in India, the statement said.
With an estimated seven crore patients struggling with chronic kidney diseases and only around 12,881 haemodialysis centers nationwide, access to proper treatment remains severely limited,
Nearly one in eleven Indians are susceptible to renal failure which is often driven by diabetes and hypertension, the officials said.
India, dubbed the 'diabetes capital of the world', adds approximately 2.5 lakh new dialysis-dependent patients annually due to advanced kidney conditions, they added.

Read also: Emcure Pharma aims to raise USD 400- USD 500 million from IPO planned for next year

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News